BACKGROUND: Children with cancer frequently have associated cachexia and malnutrition. Failure to thrive affects nearly 40% of oncology patients with advanced or progressive disease. Malnutrition can erode quality of life and adversely impact disease prognosis. Appetite stimulation and increased food intake is 1 approach to combat cancer-related cachexia. MATERIALS AND METHODS: Cyproheptadine hydrochloride (CH), an appetite stimulant, was administered to children with cancer-associated cachexia to prevent further weight loss. All participants started CH and were evaluated for response after 4 weeks. Efficacy of megestrol acetate (MA) was evaluated in patients who did not respond to CH. Medical evaluation, weight measurements, prealbumin, and serum leptin levels were preformed at follow-up visits. RESULTS: Seventy patients were enrolled. Of the 66 evaluable patients, 50 demonstrated a response to CH (average weight gain 2.6 kg and mean weight-for-age z-score change of 0.35, P=0.001). Seven of the 16 nonresponders received MA. Six patients completed 4 weeks of MA, 5 responded (average weight gain of 2.5 kg). The most commonly reported side effect of CH was drowsiness. One patient on MA developed low cortisol levels and hyperlipidemia. CONCLUSIONS: This study demonstrates that CH is a safe and effective way to promote weight gain in children with cancer/treatment-related cachexia.
BACKGROUND:Children with cancer frequently have associated cachexia and malnutrition. Failure to thrive affects nearly 40% of oncology patients with advanced or progressive disease. Malnutrition can erode quality of life and adversely impact disease prognosis. Appetite stimulation and increased food intake is 1 approach to combat cancer-related cachexia. MATERIALS AND METHODS:Cyproheptadine hydrochloride (CH), an appetite stimulant, was administered to children with cancer-associated cachexia to prevent further weight loss. All participants started CH and were evaluated for response after 4 weeks. Efficacy of megestrol acetate (MA) was evaluated in patients who did not respond to CH. Medical evaluation, weight measurements, prealbumin, and serum leptin levels were preformed at follow-up visits. RESULTS: Seventy patients were enrolled. Of the 66 evaluable patients, 50 demonstrated a response to CH (average weight gain 2.6 kg and mean weight-for-age z-score change of 0.35, P=0.001). Seven of the 16 nonresponders received MA. Six patients completed 4 weeks of MA, 5 responded (average weight gain of 2.5 kg). The most commonly reported side effect of CH was drowsiness. One patient on MA developed low cortisol levels and hyperlipidemia. CONCLUSIONS: This study demonstrates that CH is a safe and effective way to promote weight gain in children with cancer/treatment-related cachexia.
Authors: Douglas N Homnick; Benjamin D Homnick; Andrew J Reeves; John H Marks; Ronald S Pimentel; Sally K Bonnema Journal: Pediatr Pulmonol Date: 2004-08
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Ann M Davis; Kelsey Dean; Hayat Mousa; Sarah Edwards; Jose Cocjin; Osama Almadhoun; Jianghua He; Amanda Bruce; Paul E Hyman Journal: J Pediatr Date: 2016-03-03 Impact factor: 4.406
Authors: Josep M Argilés; Mireia Olivan; Sílvia Busquets; Francisco Javier López-Soriano Journal: Cancer Manag Res Date: 2010-01-22 Impact factor: 3.989
Authors: Julio C Furlan; Jefferson R Wilson; Eric M Massicotte; Arjun Sahgal; Michael G Fehlings Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 13.029